Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: Insights from the International RealiseAF Survey
Archives of Cardiovascular Diseases, Volume 107, No. 2, Year 2014
Notification
URL copied to clipboard!
Description
Background The implementation of international guidelines for antithrombotic use in atrial fibrillation (AF) in routine practice is not well known, particularly, in some parts of the world, such as the Middle East and Africa. Aim To describe and analyse the use of antithrombotics in patients with AF in routine practice. Methods The RealiseAF international cross-sectional survey enrolled 10,523 patients (with at least one documented AF episode in the preceding 12 months) from 831 sites. Participating physicians were randomly selected from physician list forms. Results Mean age was 66.6 ± 12.2 years. In 47.4% of the patients with a CHADS2 score ≥ 2, oral anticoagulants were not prescribed. Patients who had a CHADS2 score ≥ 2, permanent or persistent AF, valvular heart disease, a stroke leading to hospitalization in the previous year or treatment by a cardiologist (rather than an internist) were most likely to receive oral anticoagulants. Patients aged ≥ 75 years and those with coronary heart disease; major bleeding leading to hospitalization in the previous year or a rhythm control strategy was least likely to receive oral anticoagulants. Appropriate antithrombotic treatment was prescribed in 66.7% of the patients with a CHADS2 score ≥ 2 in the Middle East/Africa, 55.3% in Europe, 43.9% in Latin America and 31.7% in Asia. Conclusion There is substantial deviation from international guidelines in antithrombotic use for AF in routine clinical practice, with overuse and underuse of antithrombotics in about 50% of the cases and important geographical differences. These findings emphasize the need for improved medical education worldwide and a better understanding of geographical disparities in the implementation of guidelines. © 2014 Elsevier Masson SAS.
Authors & Co-Authors
Gamra, Habib
Tunisia, Monastir
Chu Fattouma-bourguiba
Murín, Ján
Slovakia, Bratislava
Univerzita Komenského V Bratislave
Chiang, Chernen
Taiwan, Taipei
National Yang-ming University Taiwan
Naditch-BrÛlé, Lisa
France, Gentilly
Sanofi S.a.
Brette, Sandrine
France, Boulogne-billancourt
Lincoln
Steg, Philippe Gabriel
France, Paris
Université Paris Cité
France, Paris
Inserm
France, Paris
Hôpital Bichat-claude-bernard Ap-hp
United Kingdom, London
Royal Brompton Hospital
Statistics
Citations: 89
Authors: 6
Affiliations: 9
Identifiers
Doi:
10.1016/j.acvd.2014.01.001
ISSN:
18752136
e-ISSN:
18752128
Research Areas
Health System And Policy
Noncommunicable Diseases
Study Design
Cross Sectional Study
Study Approach
Quantitative